Yet, exceptionally high neoantigen numbers, with robust antitumor CD8+ T cell responses have been associated with long-term survival in pancreatic cancer patients, and immune checkpoint blockade has shown clinical responses in patients with hypermutated MMR-deficient tumors (Balachandran et al., 2017; Le et al., 2017). The gene discussed is CD8A; the disease is pancreatic neoplasm.